Panelists discuss how keeping management of dermatologic adverse effects “in-house” with oncology teams is often preferable to referring patients to dermatologists, though some patients occasionally benefit from specialized care for nail issues.
Video content above is prompted by the following:
Multidisciplinary Approach to Amivantamab-Related Dermatologic Adverse Effects
Current Management Approach
The discussion highlights a preference for managing amivantamab-related dermatologic adverse effects “in-house” rather than routinely referring to dermatology for several practical reasons:
Limited dermatology appointment availability (typical 2-month wait times)
Patient burden considerations (multiple appointments, additional co-pays)
Better continuity of care when treated by the primary oncology team
Recognition that these adverse effects are treatment-related and predictable
Additional Support Resources
Several supportive care measures were identified:
Recommendations for Practice Enhancement
The summary suggests a COCOON regimen approach that appears to be a standardized protocol for managing amivantamab-related dermatologic toxicities, with emphasis on streamlining implementation through:
This approach balances comprehensive toxicity management while minimizing additional appointments and maintaining continuity within the oncology care team.